Hoencamp E, Haffmans P M, Dijken W A, Hoogduin C A, Nolen W A, van Dyck R
Psychiatric Center Bloemendaal, The Hague, The Netherlands.
J Affect Disord. 1994 Mar;30(3):219-27. doi: 10.1016/0165-0327(94)90082-5.
Depressed outpatients (n = 51) resistant to treatment with maprotiline were treated in a blind, randomized, single-centre study, for 6 weeks with either the reversible and selective monoamine oxidase A-inhibitor (MAO-A-I), brofaromine or lithium addition to maprotiline. The Hamilton Rating Scale for Depression was scored by an independent rater before and after the 6 week treatment period. No significant differences in efficacy were found between the two treatment regimes. In the patients who completed the trial, brofaromine was well tolerated with the exception of insomnia. Anticholinergic effects as well as thyroid dysfunctions (17 out of 20) were more frequent in the maprotiline/lithium group.
在一项单中心的盲法随机研究中，对51名使用麦普替林治疗无效的门诊抑郁症患者进行了为期6周的治疗，治疗方案为添加可逆性选择性单胺氧化酶A抑制剂（MAO-A-I）溴法罗明或锂盐至麦普替林中。在6周治疗期前后，由一名独立评估者对汉密尔顿抑郁量表进行评分。两种治疗方案在疗效上未发现显著差异。在完成试验的患者中，除失眠外，溴法罗明耐受性良好。在麦普替林/锂盐组中，抗胆碱能效应以及甲状腺功能障碍（20例中有17例）更为常见。
